Stock comparison
Genmab A/S
Johnson & Johnson
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
JNJ
Johnson & Johnson
Market cap
$564.11B
Sector
Healthcare
Overall winner
Johnson & Johnson JNJ
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | JNJ | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 62C | GMAB |
| Benjamin Graham | 64C | 68B | JNJ |
| Philip Fisher | 48D | 61C | JNJ |
| Peter Lynch | 25F | 65B | JNJ |
| Joel Greenblatt | 76B | 47D | GMAB |
| Charlie Munger | 68C | 61C | GMAB |
| Terry Smith | 71C | 54C | GMAB |
Side-by-side metrics
| Metric | GMAB | JNJ |
|---|---|---|
| Market cap | $16.5B | $564.11B |
| P/E (TTM) | 6.2x | 26.7x |
| EV/EBIT | 12.0x | 21.5x |
| ROIC (TTM) | 43.78% | 13.6% |
| Gross margin | 93.88% | 69.12% |
| Net margin | 18.23% | 21.83% |
| Revenue CAGR 5y | -18.45% | 4.58% |
| EPS CAGR 5y | -23.48% | 8.6% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 2.26% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 26.7x+77%
- ROIC (TTM)43.78%vs 13.6%+69%
- Debt / Equity0.1xvs 0.2x+66%
- EV/EBIT12.0xvs 21.5x+44%
JNJ leads on
- EPS CAGR 5y8.6%vs -23.48%+137%
- Revenue CAGR 5y4.58%vs -18.45%+125%
- Dividend yield2.26%vs 0.0%+100%
- Market cap$564.11Bvs $16.5B+97%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.